Hikma Pharmaceutic (OTCMKTS:HKMPF) was downgraded by stock analysts at Jefferies Group from a “hold” rating to an “underperform” rating in a report issued on Wednesday, January 10th, Marketbeat Ratings reports. Jefferies Group also issued estimates for Hikma Pharmaceutic’s FY2017 earnings at $0.87 EPS, FY2018 earnings at $0.75 EPS, FY2019 earnings at $0.82 EPS, FY2020 earnings at $0.94 EPS, FY2021 earnings at $1.01 EPS and FY2022 earnings at $1.06 EPS.
Separately, Zacks Investment Research lowered Hikma Pharmaceutic from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold”.
Hikma Pharmaceutic (HKMPF) remained flat at $$14.00 on Wednesday. Hikma Pharmaceutic has a 12-month low of $12.40 and a 12-month high of $27.50.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/04/jefferies-group-lowers-hikma-pharmaceuticals-hkmpf-to-underperform.html.
About Hikma Pharmaceutic
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.